Lansoprazole as a possible trigger of restless legs syndrome with suspected periodic limb movement disorder in a hemodialysis patient: a case report
Abstract
Restless legs syndrome (RLS) and periodic limb movement disorder (PLMD) are common in patients undergoing hemodialysis and can significantly impair sleep and daily functioning. Several medications are known to induce or exacerbate RLS/PLMD, but proton pump inhibitors (PPIs) have not been clearly implicated. We report a hemodialysis patient with dopaminergic-refractory RLS/PLMD whose symptoms improved markedly following discontinuation of lansoprazole, suggesting a possible drug-related trigger. A 76-year-old woman with end-stage renal disease due to diabetic nephropathy began hemodialysis. Lansoprazole 15 mg/day was initiated two months earlier for peptic ulcer disease. Soon afterward, she developed irresistible leg discomfort and involuntary movements during rest and sleep, occasionally extending into daytime. Symptoms were relieved by movement and fulfilled the International RLS Study Group diagnostic criteria. Rotigotine therapy was ineffective, and symptoms gradually worsened. Laboratory findings showed preserved iron status, magnesium levels, and dialysis efficiency. Due to atypical daytime symptoms and dopaminergic refractoriness, drug-induced RLS/PLMD was suspected. Methyldopa, introduced later, was discontinued first, resulting in partial improvement. Subsequent withdrawal of lansoprazole and transition to vonoprazan led to near-complete symptom resolution within 14 days, with a reduction in the RLS-6 score from 28 to 4. The Naranjo score was 5, indicating a probable…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Prediction of the In Vitro Release Curves for PLGA-Based Drug Delivery Systems with Neural Networks
- Promising Ursolic Acid as a Novel Antituberculosis Agent: Current Progress and Challenges
- Proof of principle concept for the analysis and functional prediction of rare genetic variants in the CYP2C19 and CYP2D6 genes
- Fabrication, characterization, and docking studies of furosemide-loaded nanosponges using the emulsion solvent diffusion method
- The Effect of Concomitant Administration of Proton Pump Inhibitors on the Pharmacokinetics of CDK4/6 Inhibitors in Rats: Implications for the Evaluation of Hepatic and Transporter-Mediated Drug–Drug Interactions
- Mining the Metabolic Capacity of Clostridium sporogenes Aided by Machine Learning
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.